1 / 48

CNS Infections EMERGENCY NEUROLOGY LECTURE SERIES August 24, 2011 Dr . Abdullah Al - Salti R4

CNS Infections EMERGENCY NEUROLOGY LECTURE SERIES August 24, 2011 Dr . Abdullah Al - Salti R4. CNS Infections. Case scenario Bacterial meningitis . C.T before L.P Dexamethasone used Prophylaxes. Viral encephalitis L.P procedure. CASE 1.

march
Download Presentation

CNS Infections EMERGENCY NEUROLOGY LECTURE SERIES August 24, 2011 Dr . Abdullah Al - Salti R4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CNS Infections EMERGENCY NEUROLOGY LECTURE SERIES August 24, 2011 Dr. Abdullah Al-Salti R4

  2. CNS Infections • Case scenario • Bacterial meningitis . • C.T before L.P • Dexamethasone used • Prophylaxes. • Viral encephalitis • L.P procedure.

  3. CASE 1 A 21-year-old college student was found poorly responsive in her room. She had complained of a headache for about 4 days that was refractory to NSAIDs. In the ER, temperature was 39.5°C, with BP 145/100 mmHg, HR of 112 per minute and RR of 18 per minute. She partly responded to verbal commands, localized symmetrically to noxious stimuli, and moaned incoherently. Neurological examination showed nuchal rigidity, and normal brainstem reflexes, with symmetric hyperreflexia and flexor plantar responses.

  4. CASE 1 H.P.IONSET, COURSE ,DURATION First thing to do PMH. SURGICAL HISTORY MEDICATIONS. FAMILY HISTORY. HABITES. SOCIAL .  • CONSTITIUSIONAL SYMPTOMES. • SCREEN NUEROLOGICAL SYSTEMS. • SYSTEMIC REVIEW. • WHAT IS SO FARE BEEN DONE ?

  5. Examination : • Focal neurological deficitst . • Signs of meninegeal irritation. • Signs of raised ICP. • General systemic exam. Ddx:? Investigasion ? Treatments?

  6. CNS INFECTIONS

  7. CNS INFECTIONSOverview • Life-threatening problems with high associated mortality and morbidity. • Presentation may be acute, subacute, or chronic. • Clinical findings determined by anatomic site(s) of involvement, infecting pathogen, and host response. • Vulnerability of CNS to the effects of inflammation & edema mandates prompt diagnosis with appropriate therapy if consequences to be minimized.

  8. CNS Infections • Meningitis • Bacterial, viral, fungal, chemical, carcinomatous • Encephalitis • Bacterial, viral • Meningoencephalitis • Abscess • Parenchymal, subdural, epidural

  9. INFECTIONS 4 routes which infectious agents can enter the CNS a)hematogenous spread i) most common - usually via arterial route - can enter retrogradely (veins) b)direct implantation i) most often is traumatic ii) iatrogenic (rare) via lumbar puncture iii) congenital (meningomyelocele) c)local extension (secondary to established infections) i) most often from mastoid, frontal sinuses, infected tooth, etc. d)PNS into CNS i) viruses - rabies - herpes zoster

  10. BACTERIAL MENINGITIS Meningitis refers to an inflammatory process of leptomeninges and CSF. Meningoencephalitis refers to inflammation to meninges and brain parenchyma. • Meningitis classified: a) acute pyogenic i) usually bacterial meningitis b) aseptic i) usually acute viral meningitis c) chronic i) usually TB, spirochetes, cryptococcus. • Incidence of 3 cases/100,000 population/yr (~25,000 total cases).

  11. COMMON BACTERIAL PATHOGENS BASED ON PREDISPOSING FACTOR IN PATIENTS WITH MENINGITIS Predisposing Factor Age 0-4 wK 4-12 wk 3 mo to 18 yr 18-50 yr >50 yr Common Bacterial Pathogens Streptococcus agalactiae, Escherichia coli, Listeriamonocytogenes, Klebsiellapneumoniae, Enterococcusspp., Salmonella spp. S. agalactiae, E. coli, L. monocytogenes,Haemophilusinfluenzae, Streptococcuspneumoniae, Neisseriameningitidis H. influenzae, N. meningitidis, S. pneumoniae S. pneumoniae, N. meningitidis S. pneumoniae, N. meningitidis, L..monocytogenes, aerobic gram-negative bacilli

  12. Clinical Features Signs and symptoms: • rapid onset of fever • headache • photophobia • nuchal rigidity • lethargy, malaise • altered mentation • seizure • vomiting. van de Beek D, de Gans J, Tunkel AR, et al. Community-acquired bacterial meningitis in adults. N Engl J Med 2006;354(1):44–53.

  13. Clinical Features • Study of 493 adult patients with bacterial meningitis, the presence of the ‘‘classic triad’’ of • fever, • neck stiffness, and • altered mental status was present in two-thirds of patients. • fever WAS the most common element, in 95%. (N Engl J Med 1993;328(1):21–8. ) • Older patients with S. pneumoniae meningitis are more likely to have the classic triad. Weisfelt M, van de Beek D, Spanjaard L, et al. Community-acquired bacterial meningitis in older people. J Am Geriatr Soc 2006;54(10):1500–7.

  14. Physical examination • A careful neurological examination is important to evaluate for : • focal deficits • increased intracranial pressure (ICP). • Examination should include assessment for meningeal irritation • Brudzinski’s sign • Kernig’s sign • findings include purpura or petechia of the skin, which may occur with meningococcemia.

  15. (straightening of the knee with a flexed hip resulting in back and neck pain)

  16. (passive flexion of the neck resulting in flexion of the hips and knees)

  17. Bacterial meningitis Investigations

  18. LP • Single most impt diagnostic test. • Mandatory, esp if bacterial meningitis suspected. • Tube #1 – glucose and protein • Tube #2 – cell count and differential • Tube #3 – gram stain and rountine culture, cyrptococcal antigen, AFB stain and culture • Tube #4 – VDRL, or viral studies (PCR)

  19. CSF Characteristics

  20. CT Before LP in Patients with Suspected Meningitis • 301 pts with suspected meningitis; 235 (78%) had CT prior to LP • CT abnormal in 56/235 (24%); 11 pts (5%) had evidence of mass effect • Features associated with abnl. CT were: • age >60, • immunocompromise, • H/O CNS dz, • H/O seizure w/in 7d, & • selected neuroabnls Hasbun, NEJM 2001;345:1727

  21. CT head Before LP(Cont.) • 96/235 pts (41%) who underwent CT had none of features present at baseline • CT normal in 93 of these 96 pts (NPV 97%). • Of the 3 remaining patients, only 1 had mild mass effect on CT, and all 3 underwent lumbar puncture with no evidence of brain herniation Hasbun, NEJM 2001;345:1727

  22. Consideration for lumbar puncture without neuroimaging David Somand, MDa,WilliamMeurer, MD Department of Emergency Medicine, University of Michigan, Taubman Center B1354 SPC #5303, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5303, USA • Age less than 60. • Immunocompetent. • No history of CNS disease. • No recent seizure (less than 1 week). • Normal sensorium and cognition. • No papilledema. • No focal neurologic defecits.

  23. BACTERIAL MENINGITIS Managements

  24. APPROACH TO THE PATIENT WITH SUSPECTED MENINGITIS Decision-Making Within the First 30 Minutes • Clinical Assessment • Mode of presentation • Acute (< 24 hrs) • Subacute (< 7 days) • Chronic (> 4 wks) • Historical/physical exam clues • Clinical status of the patient (ABCD) • Integrity of host defenses

  25. Management algorithm for adults with suspected bacterial meningitis.Practice Guidelines for the Management of Bacterial Meningitis

  26. BACTERIAL MENINGITISAntimicrobial Rx • Therapy is generally IV, high dose, & bolus. • Dosing intervals should be appropriate for drug being administered. • Utilize “cidal” therapy whenever possible. • Initiate therapy promptly (ie, within 30 mins)

  27. THE THERAPY OF MENINGITISCNS Penetration Good Diffusion • Penicillins • 3rd & 4th Gen Cephs • Chloramphenicol • Rifampin • TSX Poor Diffusion • Early Gen Cephs • Clindamycin • AMGs • Tetracyclines • Macrolides

  28. EMPIRIC THERAPY OF MENINGITIS IN THE ADULT

  29. EMPIRIC THERAPY OF MENINGITIS IN THE ADULT Closed head trauma S. pneumoniae Pen G 3-4 mu q4h Streptococci + Vancomycin 1-2 gm q12h

  30. EMPIRIC THERAPY OF MENINGITIS IN THE ADULT Clinical SettingLikely PathogensTherapy High risk patients S. aureusVancomycin 2-3 gm/d Compromised hosts Gram negative + Neurosurgical bacilli Ceftazidime 2 gm q8h or Open head injuryListeriaCefepime 2 gm q8h Nosocomial[Ceftriaxone 2 gm q12h] Elderly [Cefotaxime 2 gm q4h] +/- Ampicillin 2 gm q4h

  31. BACTERIAL MENINGITISDuration of ATB Rx Pathogen Duration of Rx (d) H. influenzae 7 N. meningitidis 7 S. pneumoniae 10-14 L. monocytogenes 14-21 Group B strep 14-21 GNRs 21 NEJ1997;336:708

  32. CORTICOSTEROIDS AND MENINGITIS • Recent European study in adults suggested that Rx with dexa associated with ↓ in risk of unfavorable outcome (25%→15%, RR 0.59) & in mortality (15%→7%, RR for death 0.48). • Benefit primarily pts w/S. pneumo. • Dose of dex was 10mg IV q6h X 4d; per protocol, dex given concurrent with or 15-20 mins before 1st dose of ATBs.

  33. Acute bacterial meningitis Antibiotic prophylaxis • Is recommended for high-risk exposures to patients with Neisseria or Hib meningitis.(potentially share secretions). • Regimens include : • Single-dose ciprofloxacin or ceftriaxone. • Rifampin 600 mg every 12 hours for five doses. • There is no indication for prophylaxis for exposure to pneumococcal meningitis. • Quinolone resistance has been reported to Neisseria, and this class of antibiotics is no longer recommended for prophylaxis in parts of the United States.

  34. PREDICTORS OF ADVERSE CLINICAL OUTCOMES IN PTS WITH COMMUNITY-ACQUIRED BACTERIAL MENINGITISAronin et al, AIM1998;129:862 • Retrospecitve study; 269 pts (84% culture +). • Adverse clinical outcome in 36% of pts(Death 27%, neuro deficit 9%). • ↓BP, altered MS, and seizures on presentation all independently associated with adverse clinical outcome. • Adverse outcomes in 5% of low risk pts (0 features), 37% of intermediate risk pts (1 feature), and 63% of high risk pts (2-3 features). • Delay in administration of appropriate ATB Rx also associated with adverse clinical outcome.

  35. Viral Meningitis • Very common • clinical course is less fulminant compared to bacterial • Often caused by enteroviruses Polioviruses Coxsackieviruses Echoviruses • Treatment is supportive

  36. VIRAL ENCEPHALITIS

  37. Introduction • Encephalitis is an acute inflammatory process affecting the brain • Viral infection is the most common and important cause, with over 100 viruses implicated worldwide • Symptoms • Fever • Headache • Behavioral changes • Altered level of consciousness • Focal neurologic deficits • Seizures • Incidence of 3.5-7.4 per 100,000 persons per year

  38. VIRAL ENCEPHALITIS Enteroviruses Polioviruses Coxsackieviruses Echoviruses Togaviruses Eastern equine Western equine Venezuelan equine St. Louis Powasson California West Nile Herpesviruses Herpes simplex Varicella-zoster Epstein Barr Cytomegalovirus Myxo/paramyxoviruses Influenza/parainfluenzae Mumps Measles Miscellaneous Adenoviruses LCM Rabies HIV

  39. Patient History • Detailed history critical to determine the likely cause of encephalitis. • Prodromal illness, recent vaccination, development of few days → Acute Disseminated Encephalomyelitis (ADEM) . • Biphasic onset: systemic illness then CNS disease → Enterovirus encephalitis. • Abrupt onset, rapid progression over few days → HSE. • Recent travel and the geographical context: • Africa → Cerebral malaria • Asia → Japanese encephalitis • High risk regions of Europe and USA → Lyme disease • Recent animal bites → Tick borne encephalitis or Rabies. • Occupation • Forest worker, exposed to tick bites • Medical personnel, possible exposure to infectious diseases.

  40. History cont. • Season • Japanese encephalitis is more common during the rainy season. • Arbovirus infections are more frequent during summer and fall. • Predisposing factors: • Immunosuppression caused by disease and/or drug treatment. • Organ transplant → Opportunistic infections • HIV → CNS infections • HSV-2 encephalitis and Cytomegalovirus infection (CMV) • Drug ingestion and/or abuse • Trauma

  41. Initial Signs • Headache • Malaise • Anorexia • Nausea and Vomiting • Abdominal pain

  42. Developing Signs • Altered LOC – mild lethargy to deep coma. • AMS – confused, delirious, disoriented. • Mental aberrations: • hallucinations • agitation • personality change • behavioral disorders • occasionally frank psychosis • Focal or general seizures in >50% severe cases. • Severe focused neurologic deficits.

  43. Neurologic Signs • Virtually every possible focal neurological disturbance has been reported. • Most Common • Aphasia • Ataxia • Hemiparesis. • Involuntary movements • Cranial nerve deficits (ocular palsies, facial weakness)

  44. Other Causes of Encephalopathy • Anoxic/Ischemic conditions • Metabolic disorders • Nutritional deficiency • Toxic (Accidental & Intentional) • Systemic infections • Critical illness • Malignant hypertension • Mitochondrial cytopathy (Reye’s and MELAS syndromes) • Hashimoto’s encephalopathy • Traumatic brain injury • Epileptic (non-convulsive status) • CJD (Mad Cow)

  45. Differential Diagnosis • Distinguish Etiology • (1) Bacterial infection and other infectious conditions • (2) Parameningeal infections or partially treated bacterial meningitis • (3) Nonviral infectious meningitides where cultures may be negative (e.g., fungal, tuberculous, parasitic, or syphilitic disease) • (4) Meningitis secondary to noninfectious inflammatory diseases

  46. VIRAL ENCEPHALITIS DIAGNOSIS. LP: • CSF usually colorless - slightly  pressure - initially a neutrophilic pleocytosis, which rapidly converts to lymphocytes - proteins are  - glucose is normal • PCR for HSE and other viral infection is diagnostic .

  47. VIRAL ENCEPHALITIS DIAGNOSIS. MRI: • May show temporal or orbitofrontal cortex enhancement or edema in HSE. • In most other acute viral encephalities , neuroimaging finding are nonspecific. • Can exclude subdural bleeds, tumor, and sinus thrombosis. EEG: • Non specific • Diffuse slowing . • Focal abnormalities in the temporal region . HSV

  48. Treatment. • Only HSV disease has specific therapy available. Acyclovir is capable of improving patient outcome. dose : 10 mg/kg intravenously every 8 hours. Duration 14-21 days. • ganciclovir can be used in CMV infections. • pleconaril has shown promise in enteroviral. Outcomes • Outcomes are variable depending on etiology. • EEE and St. Louis encephalitis generally have high mortality rates and Severe neurologic sequelae among survivors. • WNV is associated with significant morbidity and morality. • Mortality of HSV encephalitis before acyclovir was 60% to 70%, and with treatment approximately 30%. • Cognitive disability,seizures, and motor deficits are common sequelae seen among survivors

More Related